Abstract
The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy. However, there are large variations among patients in both the therapeutic efficacy and side effects of these drugs. Pharmacogenomics is the study of the role of inheritance in this variation and genetic variation in tamoxifen response represents one of the most striking examples of the potential clinical importance of pharmacogenomics. Tamoxifen requires “metabolic activation” catalyzed by cytochrome P450 2D6 (CYP2D6) to form hydroxylated metabolites—4-hydroxytamoxifen and endoxifen (N-desmethyl-4-hydroxytamoxifen)—both of which are much more potent than is the parent drug. However, CYP2D6 is genetically polymorphic. Approximately 5–8% of Caucasian subjects are CYP2D6 “poor metabolizers” on a genetic basis and, as a result, are relatively unable to catalyze tamoxifen hydroxylation. These same subjects appear to have poorer outcomes when treated with tamoxifen than do CYP2D6 “extensive metabolizers”. These data led the US Food and Drug Administration (FDA) to hold public hearings in 2006 on the inclusion of this pharmacogenomic information in tamoxifen labeling. However, a series of important questions still remains to be addressed with regard to tamoxifen pharmacogenomics. There have also been preliminary attempts to study the pharmacogenomics of aromatase inhibitors, including the application of a genotype-to-phenotype research strategy designed to explore the nature and extent of common DNA sequence variation in the CYP19 gene that encodes aromatase. Those results—together with our current level of understanding of tamoxifen pharmacogenomics—will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science and translation. Annu Rev Genomics Hum Genet 2006; 7:223–245.
Hayes DF. Why endocrine therapy? In: Miller WR, Ingle JN, eds. Endocrine Therapy in Breast Cancer. New York: Marcel Dekker, Inc.; 2002:3–14.
Weinshilboum RM. The therapeutic revolution. Clin Pharmacol Ther 1987; 42:481–484.
Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291:1304–1351 [Erratum, Science 2001; 1292:1838].
Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860–921 [Errata, Nature 2001; 2411:2720, 2412:2565].
Weinshilboum R. Inheritance and drug response. New Engl J Med 2003; 348:529–537.
Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 85(23):1758–1764.
Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356(9257):2059–2063.
Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of luoxetine for treatment of hot flashes. J Clin Oncol 2002; 20(6):1578–1583.
Stearns V, Beebe KL, Iyengar M et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289(21):2827–2834.
Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85(2):151–159.
Lim YC, Desta Z, Flockhart DA et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55(5):471–478.
Lim YC, Li L, Desta Z et al. Endoxifen, a secondary metabolite of tamoxifen and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006; 318(2):503–512.
Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36):9312–9318.
Bonanni B, Macis D, Maisonneuve P et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen. Trial. J. Clin Oncol 2006; 24(22):3708–3709.
Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101(1):113–121.
Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2003; 9(5):431–438.
Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982; 42(1):317–323.
Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res Treat 1982; 2(2):123–138.
Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25(11):1679–1691.
Bertilsson L, Lou YQ, Du YL et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388–397 [Erratum, Clin Pharmacol Ther 1994; 1955:1648].
Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97(1):30–39.
Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80(1):61–74.
Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005; 97(6):412–413.
Young D. Genetics examined in tamoxifen’s effectivness. Am J Health Syst Pharm 2006;63(23):2286, 2296.
Van Poznak CH, Hayes DF. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? J Natl Cancer Inst 2006; 98(18):1261–1263.
Takimoto CH. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Nat Clin Pract Oncol 2007; 4(3):152–153.
Choi JY, Nowell SA, Blanco JG et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006; 7(4):613–624.
Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 2007; 8(2):119–127.
Beverage JN, Sissung TM, Sion AM et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96(9):2224–2231.
Wegman P, Vainikka L, Stål O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7(3):R284–R290.
Wegman P, Elingarami S, Carstensen J et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9(1):R7.
Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91(3):249–258.
Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen in relation to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; in press.
Hartman AR, Helft P. The ethics of CYP2D6 testing for patients considering tamoxifen. Breast Cancer Res 2007; 9(2):103.
Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348(24):2431–2442.
Swain SM. Aromatase inhibitors—a triumph of translational oncology. N Engl J Med 2005; 353(26):2807–2809.
Ma CX, Adjei AA, Salavaggione OE et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005; 65(23):11071–11082.
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22):2285–2293.
Wang L, Weinshilboum RM. Thiopurine S-methyltransferase (TPMT) pharmacogenetics: insights, challenges and future directions. Oncogene Rev 2006; 25(11):1629–1938.
Innocenti F, Ratain MJ. “Irinogenetics” and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 2004; 75(6):495–500.
Zeggini E, Weedon MN, Lindgren CM et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316(5829):1336–1341.
Scott LJ, Mohlke KL, Bonnycastle LL et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316(5829):1341–1345.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, Novartis Institutes of BioMedical Research et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316(5829):1331–1336.
Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447(7148):1087–1093.
Desta Z, Ward BA, Soukhova NV et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310(3):1062–1075.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Weinshilboum, R. (2008). Pharmacogenomics of Endocrine Therapy in Breast Cancer. In: Berstein, L.M., Santen, R.J. (eds) Innovative Endocrinology of Cancer. Advances in Experimental Medicine and Biology, vol 630. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78818-0_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-78818-0_14
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78817-3
Online ISBN: 978-0-387-78818-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)